临床阶段精准肿瘤企业Repare Therapeutics Inc.（纳斯达克：RPTX）宣布与瑞士生物制药公司Debiopharm就首创PKMYT1抑制剂Lunresertib签订全球独家授权协议。根据协议条款，Repare将获得1000万美元首付款，并有机会获得最高2.57亿美元的里程碑款项及全球净销售额个位数百分比的特许权使用费。
此次合作深化了两家公司现有研究基础，将重点探索Lunresertib与Debiopharm旗下WEE1抑制剂Debio 0123的协同治疗效果。协议签署后，Debiopharm将接手MYTHIC临床研究的赞助工作，并全面负责Lunresertib后续开发活动。
目前两项关键I期临床试验进展顺利：针对晚期实体瘤的LIONS试验和针对子宫内膜癌的POLAR试验，预计将在2025年下半年公布初步数据。该合作标志着PKMYT1靶向疗法商业化进程取得重大突破，创下该靶点药物授权交易金额新纪录。
（注：本资讯基于企业公告信息整理，仅供参考不构成投资建议）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.